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INTRODUCTION
Since the approval of the da Vinci robotic surgical system 
(Intuitive Surgical Inc., Sunnyvale, CA, USA) by the Food and 
Drug Administration for use in gynecologic procedures in 
April of 2005, over 100 publications have explored the role of 
robotic surgery in gynecologic malignancies. Worldwide, ro-
botic technology is being rapidly adopted with the number of 
robotic-assisted procedures being performed nearly tripling 
from 80,000 in 2007 to 205,000 in 2009. In a similar time frame, 
the number of da Vinci robotic systems installed in US hospi-
tals grew by approximately 75% from 800 to around 1,400 [1]. 
The benefits of robotic surgery as a minimally invasive surgical 
technique parallel those of traditional laparoscopy, with the 
added advantages of overcoming several barriers to the use 
of laparoscopy, such as limitations of the human hand (seven 
degrees of movement and elimination of hand tremors), elim-
ination of the fulcrum effect of laparoscopy (the robotic arms 
imitate the movements of the surgeon’s hand), improved 
visualization (three-dimensional stereoscopic imaging), and 
increased independence of the operating surgeon, thus 
enabling the robotic-assisted management of gynecologic 
malignancies to become more widely utilized. In a recent 
survey of the members of the Society of Gynecologic Oncolo-
gist (SGO) examining the trends in laparoscopic and robotic 
surgery, 27% of respondents indicated that they performed 
robotic-assisted surgery, and 66% indicated that they planned 
to increase their use of robotic-assisted surgery in the future 
citing limited access to robotic systems as a common reason 
for not already adopting robotic technology [2]. In addition 
to limited access primarily secondary to cost, robotic surgery 
has several other potential drawbacks including lack of haptic 
feedback, bulky machine habitus, and need for additional staff 
and training. Robotic technology in gynecology remains in its 
infancy with most articles supporting its use being limited to 
case series, retrospective cohorts and case control studies. The 
purpose of this review is to summarize the available literature 
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The objective of this article was to review the published scientific literature pertaining to robotic surgery and its applications 
in gynecologic malignancies and to summarize the impact of robotic surgery on the field of gynecologic oncology. 
Summarizing data from different gynecologic disease-sites, robotic-assisted surgery is safe, feasible, and demonstrates 
equivalent histopathologic and oncologic outcomes. In general, benefits to robotic surgery include decreased blood loss, fewer 
perioperative complications and decreased length of hospital stay. Disadvantages include accessibility to robot surgical systems, 
decreased haptic sensation and fixed cost as well as cost of disposable equipment. As robotic surgery becomes readily available 
it will be imperative to develop standardized training modalities. Further research is needed to validate the role of robotic 
surgery in the treatment of gynecologic malignancies.
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on robotic surgery and its impact on the field of gynecologic 
oncology. 
CERVICAL CANCER
Since the first published report of robotic radical hysterecto-
my in 2006 [3], several publications have evaluated the safety, 
feasibility and efficacy of a robotic-assisted laparoscopic radi-
cal hysterectomy and bilateral pelvic lymphadenectomy for 
the treatment of early stage (IA2 and IB1) cervical cancer. In a 
pilot case-control study designed to evaluate the safety and 
efficacy of robotic radical hysterectomy and bilateral pelvic 
lymphadenectomy among patients with early stage cervical 
cancer, there was no significant difference in operative time, 
number of lymph nodes excised, and length of the excised 
parametrial tissue compared to patients who underwent lapa-
roscopic radical hysterectomy [4]. There was, however, signifi-
cantly less blood loss (71 mL vs. 160 mL) and shorter length of 
hospital stay (4 days vs. 8 days) in the robotic-assisted group 
(p<0.05). In a retrospective clinical review of ten early stage 
cervical cancers, Kim et al. [5], report successful completion of 
each attempted operation with no conversion to laparotomy 
with a median operative time of 207 minutes (range, 120 to 
240 minutes), a median docking time of 26 minutes (range, 10 
to 45 minutes), mean estimated blood loss of 355 mL, and an 
average of 27.6 pelvic lymph nodes removed (range, 12 to 52). 
More importantly there were no ureteral injuries or fistulae. 
Collectively, these initial studies demonstrated the safety and 
feasibility of performing radical hysterectomies with a robotic-
assisted approach.
Several comparative analyses of different modalities of 
radical hysterectomy also exist in the literature. Nezhat et al. 
[6], compared intraoperative, pathologic and postoperative 
outcomes of 13 patients who underwent robotic radical hys-
terectomy to 21 patients who underwent laparoscopic radical 
hysterectomy, and found no significant different in operative 
time, mean estimated blood loss and pelvic nodal counts. At 
the conclusion of follow-up, neither group had experienced a 
recurrence, leading the authors to conclude that robotic radi-
cal hysterectomy appears to be equivalent to laparoscopic 
radical hysterectomy. In a case-control study, Boggess et al. [7], 
compared 51 patients who underwent robotic radical hyster-
ectomy with 49 patients who underwent open radical hyster-
ectomy and found significant differences in estimated blood 
loss, operative time and nodal counts all in favor of the robotic 
radical hysterectomy cohort, leading the authors to conclude 
that robotic radical hysterectomy is feasible and may be fa-
vorable over open radical hysterectomy in patients with early 
stage cervical cancer. 
In a recently published retrospective comparative series of 
robotic radical hysterectomy with laparoscopic radical hyster-
ectomy or open abdominal radical hysterectomy, Magrina et 
al. [8], provide the only comparison of the three available sur-
gical modalities. The mean operative times for patients in the 
robotic, laparoscopic, and open cohorts were 190, 220, and 
167 minutes, respectively; the mean estimated blood loss was 
133, 208, and 443 mL, respectively; and the mean length of 
stay was 1.7, 2.4, and 3.6 days, respectively. There were no re-
ported differences in intraoperative or postoperative compli-
cations and no conversions in the minimally invasive groups. 
Despite the presumed equivalency of a minimally invasive 
sur  gical approach to radical hysterectomy, to date there is no 
completed prospective comparison that is adequately po  wered 
to classify a robotic or laparoscopic radical hysterectomy as an 
equivalent surgical approach to open radical hysterectomy. 
A multicenter phase III randomized clinical trial comparing 
ro  botic or laparoscopic radical hysterectomy with abdominal 
ra  dical hysterectomy in patients with early stage cervical can-
cer is currently underway [9]. The aim of this study is to show 
the equivalence of the minimally invasive surgical approach 
ver  sus the abdominal approach with a two phase protocol. 
The primary endpoint of the first phase is rate of enrollment 
and the primary endpoint of the second phase is to deter-
mine equivalence with respect to disease-free survival with 
80% power. Secondary endpoints include treatment-related 
mor  bi  dity, cost and cost effectiveness, patterns of recurrence, 
quality of life, pelvic floor function, feasibility of intraoperative 
sentinel lymph node sampling, and overall survival. 
Given the stated advantages of minimally invasive surgery, 
employment of the da Vinci robotic surgical system has given 
surgeons the opportunity to perform complex gynecologic 
oncology procedures through a minimally invasive approach. 
One such example of this is radical trachelectomy. Radical 
trachelectomy is an appropriate alternative to radical hyste-
rec  tomy in appropriately selected patients with early stage 
cervical cancer. Although reports of laparoscopic radical tra-
ch  electomy exist [10,11], the laparoscopic approach has not 
been widely accepted secondary to the complexity of the 
pro  cedure and the required advanced skill of the surgeon. 
With the advantages in surgical instrumentation the robotic 
sur  gical system affords, robotic radical trachelectomy appears 
to be a feasible alternative to the open or vaginal approach. 
In the largest reported series of patients who underwent 
robo  tic radical trachelectomy to date, the authors compared 
the robotics approach to historical controls and found that 
the robotics approach was associated with less blood loss, a 
lower transfusion rate, fewer intraoperative and postoperative Alpa M. Nick, et al.
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complications and a shorter length of hospitalization without 
compromising histopathologic outcomes such as parametrial 
length or node counts [12].
Failure to detect occult nodal metastases in patients with 
locally advanced cervical cancer (IB2-IVA) can lead to subopti-
mal treatment. In a prospective correlation of surgical findings 
with positron emission tomography/computed tomography 
(PET/CT), patients underwent preoperative PET/CT followed 
by laparoscopic extraperitoneal para-aortic lymphadnectomy 
[13]. Among the 26 patients with negative pelvic and para-
aortic lymph nodes on PET/CT, 3 (12%) had histopathologi-
cally positive para-aortic nodes. Of the 27 patients with posi-
tive pelvic but negative para-aortic lymph nodes on PET/CT, 
6 (22%) had histopathologically positive para-aortic lymph 
nodes. Eleven (18.3%) patients had a treatment modification 
based on surgical findings, highlighting the importance of sur-
gical staging in patients with locally advanced cervical cancer. 
The extraperitoneal approach to para-aortic lymphadenecto-
my overcomes limitations of the transpertioneal approach in-
cluding, obesity, short intestinal mesentery, distended bowel, 
intestinal adhesions. Robotic technology provides additional 
advantages over traditional laparoscopic instrumentation, 
particularly when working in a limited surgical field during 
extraperitoneal para-aortic lymphadnectomy. Margina et al. 
[14] described the development of robotic extraperitoneal 
lymphadenectomy using two female torso cadavers and the 
feasibility of selective aortic lymphadenectomy in a patient 
with advanced cervical cancer. Similarly, Vergote et al. [15] 
report on the first series of robotic retroperitoneal para-aortic 
lymphadenectomy in patients with advanced cervical cancer, 
and concluded that the robotic procedure was technically 
easier than the laparoscopic approach. 
ENDOMETRIAL CANCER
Because of the associated risk factors for endometrial can-
cer, including obesity and multiple medical comorbidities, 
patients with endometrial cancer often represent relatively 
unfit surgical candidates at greater risk for surgical morbidity. 
Minimally invasive surgery has been championed as a means 
of reducing surgical morbidity. In a survey to members of the 
SGO examining trends in laparoscopy and robotic surgery, 
there was a 12% increase in the number of SGO members 
who preferred to use laparoscopy in oncologic cases in which 
both laparoscopy and laparotomy offered equal results, with 
surgical staging of endometrial cancer being the most com-
mon indication for laparoscopy [2]. 
In the same survey, 27% of respondents indicated that they 
used the robot surgical system for gynecologic procedures. 
Reasons for the expanded use of minimally invasive surgery 
include studies documenting the feasibility, effectiveness 
and equivalency of a laparoscopic surgical approach in pa-
tients with early stage endometrial cancer. Zullo et al. [16,17] 
performed a randomized trial comparing laparoscopy and 
laparotomy in patients with early stage uterine cancer, and 
found that laparoscopy was as feasible and safe as the open 
approach with no difference in recurrence rates or death 
and a significant improvement in quality of life for the first 3 
years after surgery. In a prospective comparison of laparos-
copy to laparotomy for endometrial cancer staging, the Lap-
2 trial, conducted by the Gynecologic Oncology Group (GOG), 
demonstrated the feasibility of laparoscopy with equivalent 
positive cytology rates, proportion of advanced stage diag-
noses, and node positivity compared to laparotomy [18]. In 
addition, laparoscopy had an improved safety profile with 
fewer grade ≥2 postoperative events and shorter hospital stay. 
Laparoscopy was associated with less postoperative pain, ear-
lier resumption of normal activity, earlier return to work, and 
significant improvement in quality of life. Tozzi et al. [19] were 
the first to report on differences in survival outcomes among 
patients undergoing laparoscopic versus open approach to 
endometrial cancer. Overall survival rates showed no signifi-
cant difference between the two groups: 86% in the lapa-
rotomy group compared to 90% in the laparoscopy group, 
respectively. 
Although prospective comparisons of robotic endometrial 
cancer surgery to other modalities of surgical staging are 
lacking, data demonstrating the benefits of laparoscopy can 
be extrapolated and combined with existing reports regard-
ing robotics and endometrial cancer surgery. Paley et al. [20] 
report on the surgical outcomes of the first 377 consecutive 
cases of women who underwent endometrial cancer stag-
ing with robotic surgery compared to 131 women who un-
derwent abdominal hysterectomy with surgical staging in 
the year prior to initiation a robotic surgery program at their 
institution. There were no significant differences between 
the groups with respect to age, BMI, medical comorbidities, 
or number of previous abdominal surgeries. Operative times 
were longer in the robotic surgery group, but nodal counts, 
length of stay and estimated blood loss all favored the ro-
botics cohort. In addition, women undergoing open surgery 
experienced significantly higher major complications com-
pared to women undergoing robotics surgery (26% vs. 6.4%, 
p<0.001). The most significant reduction was in the incidence 
of wound separation or dehiscence, infectious complications, 
and ureteral injury or acute renal failure in the robotic surgery 
group. The authors estimate that the incorporation of robotic The impact of robotic surgery on gynecologic oncology
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surgery into their minimally invasive surgery program was 
most significant for endometrial cancer patients with a 12.5-
fold increase in endometrial cancer patients receiving staging 
surgery via a robotic minimally invasive surgical approach. 
This shift towards robotic surgery for endometrial cancer is 
similar to the experience of other minimally invasive surgical 
programs across the country [21]. A potential reason for rapid 
incorporation of a robotics approach to endometrial cancer 
staging procedures is the steeper learning curve in compari-
son to laparoscopic hysterectomy with lymphadenectomy. 
Lim et al. [22] compared the learning curve and outcomes of 
the first 122 patients who underwent a robotic hysterectomy 
with lymphadenectomy to the first 122 patients who under-
went a similar laparoscopic approach. They found robotic hys-
terectomy with lymphadenectomy had a faster learning curve 
in comparison to laparoscopic hysterectomy with lymphad-
enectomy with comparable adequacy of surgical staging be-
tween the two surgical methods. In addition, robotic hyster-
ectomy with lymphadenectomy was associated with shorter 
hospitalization, less blood loss, fewer intraoperative and major 
complications, and a lower rate of conversion to an open pro-
cedure.
OVARIAN CANCER
Given the effectiveness and feasibility of minimally invasive 
surgery in the management and staging of other early gyne-
cologic malignancies, there is now expanding interest of the 
role of minimally invasive surgical approaches in the man-
agement of ovarian cancer. There is controversy surrounding 
implementation of minimally invasive surgical approaches 
with regards to ovarian cancer management secondary to the 
concern that meticulous exploration of the peritoneal cavity is 
neither safe nor feasible using laparoscopy because of limited 
range of motion, visibility and haptic sensation. Consequently, 
there is limited data regarding the efficacy of minimally inva-
sive surgery and specifically robotic surgery in the manage-
ment of ovarian cancer. 
Borderline ovarian tumors account for approximately 10-15% 
of cases of early stage epithelial ovarian cancer, and as a result 
surgical staging of borderline ovarian tumors is recommended 
secondary to the risk of under diagnosis of invasive epithelial 
ovarian cancer on frozen section. In the largest review to date, 
Fauvet et al. [23] compared women with ovarian borderline 
tumors who underwent surgical staging with laparoscopy 
to laparotomy retrospectively, and found that women in the 
laparoscopy group had a significantly lower rate of complete 
surgical staging likely secondary to a high rate of conservative 
surgery in the laparoscopy group. However, there was no sig-
nificant difference in recurrences rate between patients in the 
laparoscopy group in comparison to the laparotomy group 
(12.1% vs. 9.1%). There was a relatively high rate of con  version to 
open in the laparoscopy group (28.2%) secondary to expected 
ovarian cancer, large volume tumor and adhesions, stressing 
the importance of adequate patient selection when attempt-
ing a minimally invasive surgical approach. 
Approximately 15% of women with epithelial ovarian cancer 
will have early stage disease at diagnosis and require com-
prehensive surgical staging to provide adequate prognostic 
information and treatment planning. Patients with presumed 
early stage ovarian cancer identify a cohort of epithelial ovar-
ian cancer patients that could potentially benefit from the 
reduced morbidity of a minimally invasive surgical approach. 
Tozzi et al. [24] identified 24 patients with FIGO stage IA or IB 
ovarian or fallopian tube carcinoma who underwent compre-
hensive laparoscopic staging. There were no intraoperative 
complications. The mean operative time was 176 minutes. 
The mean number of pelvic lymph nodes removed was 19.8 
and the mean number of para-aortic lymph nodes removed 
was 19.6. The mean progression-free survival rate was 91.6% 
and the overall survival rate was 100%. In a second study per-
formed by the GOG, the feasibility of completion laparoscopic 
staging for women with incompletely staged ovarian, fal-
lopian tube, or primary peritoneal carcinoma was examined. 
Women who underwent laparoscopy had significantly less 
estimated blood loss and shorter hospital stay than women 
who underwent laparotomy with equivalent operative times 
and numbers of lymph nodes obtained [25]. Of note in this 
study, there was a relatively high conversion rate (23%), a 
high complication rate (19%), and lack of follow-up data on 
disease progression and overall survival. Nezhat et al. [26] per-
formed a retrospective review of 36 patients who underwent 
laparoscopic staging for presumed early stage ovarian and 
fallopian tube carcinoma. There were 4 retrospective postop-
erative complications, and 78% had their disease upstaged. 
The mean follow-up was 55.9 months and there were 3 recur-
rences in patients who underwent conservative surgery with 
an overall survival rate of 100%. Secondary to the proposed 
technological advantages of robotic surgery, Magrina et al. [27] 
performed a retrospective case-control analysis of 25 patients 
with epithelial ovarian cancer undergoing robotic surgical 
treatment in comparison with patients treated by laparoscopy 
and laparotomy. Patients in this study were not limited to ap-
parent early stage disease. There was a significant increase in 
the mean operative time among patients in the robotics co-
hort. In contrast, patients in the robotic surgery group had less 
blood loss and the shortest mean length of hospital stay com-Alpa M. Nick, et al.
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pared to laparoscopy or laparotomy. Patients were subdivided 
according to the extent of surgery by the type and number of 
procedures required to achieve adequate cytoreduction, and 
they concluded that laparoscopy or robotics are preferable to 
laparotomy for patients with ovarian cancer requiring primary 
tumor excision along with one additional major procedure. 
Laparotomy is preferred for those patients requiring two or 
more additional major procedures. As one would expect, 
removal of all disease, and not the surgical approach, is the 
most important factor in influencing survival. Despite limited 
retrospective data, it does appear that minimally invasive 
surgical staging of presumed early stage ovarian cancer is 
safe and effective when performed by a trained gynecologic 
oncologist; however, the disadvantages of robotic surgery will 
likely limit application of the robotic surgery approach to care-
fully selected patients with epithelial ovarian cancer.
COST OF ROBOTIC SURGERY
In reviewing the available literature it becomes apparent 
that robotic technology is safe and allows completion of more 
complex surgical procedures via a minimally invasive surgical 
approach, but at relatively high costs. In a recent cost compar-
ison of robotic surgery, laparoscopy, and laparotomy, cost esti-
mates were fit into three separate models: a societal perspec-
tive, and a hospital perspective with and without robotic costs 
included [28]. The societal model included in patient hospital 
cost, robotic expenses, lost wages of patient and caregiver 
cost. The hospital models included inpatient hospital costs 
with and without the cost of the robot. As one would expect, 
from an economic perspective, laparoscopy was the least 
costly approach among all three models utilized in this study. 
In addition, from the societal perspective, the shorter hospital 
stay and recovery time associated with minimally invasive sur-
gery is reflected in the lower overall cost of both laparoscopy 
and robotics from a societal perspective when compared to 
the open approach. In both of the hospital models, with and 
without robotic cost, the traditional laparoscopic techniques 
remained the least expensive technique. The most significant 
contributor causing robotic surgery to remain more expensive 
than traditional laparoscopy was the cost of disposable equip-
ment. Disposable equipment for traditional laparoscopy ver-
sus robotic surgery was $1,138 and $2,210, respectively, not 
including the upfront fixed cost of the robot ranging from $1 
million to $2.5 million per unit, or the cost of the maintenance 
contract [1]. Unfortunately, despite the existence of unique di-
agnosis and procedure codes for robotic-assisted procedures, 
there is no higher reimbursement rate for robotic assisted 
procedures from US Medicare or private insurers. 
IMPACT ON TRAINEE EDUCATION
In a recent survey of gynecologic oncology training prog-
rams, 78% of fellows in training reported a need for more 
mi  ni  mally invasive surgical training [29]. As new surgical te-
ch  niques and instrumentation are brought to the forefront, 
effi  cient training of residents and fellows is imperative. With 
the constraints of the 80 hour work week restrictions, trainees 
have less exposure to a variety of surgical cases, stressing the 
importance of a defined surgical curriculum. Development of 
training protocols serves as a dual purpose in that it also pro-
vides trainees with objective documentation of competency 
as they seek jobs at the completion of training and credential-
ing in robotic surgery. Lastly, medical simulation training is the 
focus of recent governmental expenditures in that the Agency 
for Healthcare Research and Quality has awarded $5 million in 
grants for simulation research projects [30]. 
In a recent systematic review of randomized controlled tri  als 
evaluating the effectiveness of virtual reality training for lapa-
roscopic surgery, Gurusamy et al. [31], concluded that virtual 
reality training resulted in a greater reduction in operating 
time, error and unnecessary movements in com  parison to 
standard laparoscopic training in which the trainee observes 
an experienced surgeon. In a separate study, trainees in an ob-
stetrics and gynecology residency program were randomized 
to receive proficiency-based virtual reality simulator training 
in laparoscopic salpingectomy or standard clinical education 
[32]. Those in the simulator trained group performed superi-
orly to those in the standard education group. Defined robotic 
surgical training protocols are now starting to emerge. Geller 
et al. [30] describe a protocol that includes online instruction 
and 2 hands-on modules that evaluate platform set-up and 
surgical skills with plans to reassess the effectiveness of their 
model as their trainees progress through residency and fel-
lowship with an ultimate goal of establishing a proficiency 
level. 
CONCLUSIONS
Our review of the literature establishes a role for robotic sur-
gery in early stage cervical and endometrial cancer, advanced 
cervical cancer, fertility sparing procedures for the treatment 
of cervical cancer, and early stage ovarian cancer. Surgeons 
should expect further research to validate the application of The impact of robotic surgery on gynecologic oncology
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robotic surgery in the treatment of these particular malignan-
cies and clinical scenarios. 
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